Arrowhead Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 7, 2023 and accepted by EDGAR at Aug 7, 2023, 16:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $15.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2022-10-01 to 2023-06-30 | $224.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$102.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-10-01 to 2023-06-30 | −$96.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $5.2m | us-gaap:InterestExpense |
| Interest expense | 9 months2022-10-01 to 2023-06-30 | $13.1m | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-01 to 2023-06-30 | $742.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-10-01 to 2023-06-30 | $759.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$102.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-10-01 to 2023-06-30 | −$95.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | −$0.96 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-10-01 to 2023-06-30 | −$0.90 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | −$0.96 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-10-01 to 2023-06-30 | −$0.90 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 107,004,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-10-01 to 2023-06-30 | 106,597,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-10-01 to 2023-06-30 | −$128.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-10-01 to 2023-06-30 | $112.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-06-30 | $105.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $470.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $795.9m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $70.2m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2023-06-30 | $364.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-027771. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.